Compare Impinj Inc (PI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs Sana Biotechnology Inc — how do they compare? Impinj Inc trades at $187.41 (market cap $5.60B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: Impinj Inc is far larger — about 6.7× Sana Biotechnology Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and Sana Biotechnology Inc for 23 Days on average.
| PI | SANA | |
|---|---|---|
Market Cap | $5.60B | $836.71M |
Volume | 9,929 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $241.91 | $5.92 |
52-Week Low | $91.34 | $2.68 |
Typical Hold Time | 22 Days | 23 Days |
Enterprise Value | $5.73B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $186.53, down 2.36% with a bullish technical outlook despite negative profitability metrics. The stock shows strong analyst support with 16 buy ratings and a $178.83 consensus target. Recent Q2 2026 earnings beat expectations with $0.86 EPS, while revenue growth continues but net margins remain negative at -7.26%. The company maintains solid cash flow from operations of $58.75M in 2025.
Investment outlook balances growth potential against profitability challenges. The RAIN RFID technology market offers expansion opportunities, but elevated valuations (P/S 14.83) and negative ROE (-12.87%) present risks. Near-term catalysts include Q3 2026 results, while competitive pressures and execution risks require monitoring for sustained shareholder value creation.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
